Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.56 |
| ▸ | PPARA | Q07869 | 12/20 | 0.56 |
| ▸ | PPARD | Q03181 | 10/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | GALK1 | P51570 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096692 | 0.91 | PPARG (0.52) | PPARGPPARAPPARDEPHX2GALK1 | |
| SCHEMBL12096748 | 0.91 | PPARG (0.52) | PPARGPPARAPPARDEPHX2NR1H4 | |
| SCHEMBL12096616 | 0.89 | PPARG (0.52) | PPARGPPARAPPARDACLYGALK1 | |
| SCHEMBL12096713 | 0.87 | PPARG (0.53) | PPARGPPARAPPARDRORC | |
| SCHEMBL12096773 | 0.87 | PPARG (0.52) | PPARGPPARAPPARDACLYRORC | |
| SCHEMBL12096772 | 0.87 | PPARG (0.54) | PPARGPPARAPPARDRORC | |
| SCHEMBL12099650 | 0.86 | PPARG (0.52) | PPARGPPARAPPARDGALK1RORC | |
| SCHEMBL27950300 | 0.84 | PPARG (0.40) | PPARGPPARAPPARDEPHX2NR1H4 | |
| SCHEMBL12096755 | 0.83 | PPARG (0.53) | PPARGPPARAPPARDNR1H4RORC | |
| SCHEMBL12096654 | 0.83 | PPARG (0.49) | PPARGPPARAPPARDGALK1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | PPARG 423/4885PPARA 564/4885PPARD 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.